{{translating|time=2017-08-26}}
{{medical}}
{{Infobox medical condition (new)
 | name           = 多囊卵巢症候群
 | image          = PCOS.jpg
 | caption        = [[医学超声检查|超聲波掃描]]下的多囊卵巢綜合症。
 | field          = [[婦科學|婦科學]]
 | synonyms       = 高雄性激素無排卵（Hyperandrogenic anovulation，HA）<ref name="KollmannMartins2014">{{cite journal | authors = Kollmann M, Martins WP, Raine-Fenning N | title = Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation | journal = Hum. Reprod. Update | volume = 20 | issue = 3 | pages = 463–4 | year = 2014 | pmid = 24516084 | doi = 10.1093/humupd/dmu005 }}</ref>、斯-李二氏症（Stein–Leventhal syndrome）<ref>{{cite web|title=USMLE-Rx|year=2014|publisher=MedIQ Learning, LLC|quote=Stein-Leventhal syndrome, also known as polycystic ovary syndrome (PCOS), is a disorder characterized by hirsutism, obesity, and amenorrhea because of luteinizing hormone-resistant cystic ovaries.}}</ref>
| symptoms        = [[月經|月經]]失調、[[經血過多|經血過多]]、[[多毛症|多毛症]]、[[痤疮|痤疮]]、骨盆痛、[[不孕|不孕]]、[[黑棘皮症|黑棘皮症]]<ref name=NIH2013Sym/>
| complications   = [[2型糖尿病|2型糖尿病]]、[[肥胖症|肥胖症]]、[[阻塞性睡眠呼吸暂停|阻塞性睡眠呼吸暂停]]、[[心血管疾病|心血管疾病]]、[[情感障礙|情感障礙]]、[[子宫内膜癌|子宫内膜癌]]<ref name=NIH2013Def/>
| onset           = 
| duration        = 長期<ref name=NIH2013Cure/>
| causes          = 遺傳或環境因素<ref name=De2016/><ref name=Endo2006/>
| risks           = [[肥胖症|肥胖症]]、運動不足、家族病史<ref name=NIH2013Epi/>
| diagnosis       = 無排卵、高[[雄激素|雄激素]]、[[卵巢囊腫|卵巢囊腫]]<ref name=NIH2013Def/>
| differential    = [[先天性腎上腺增生症|腎上腺增生症]]、[[甲狀腺機能低下症|甲狀腺機能低下症]]、{{tsl|en|hyperprolactinemia|高泌乳素血症}}<ref name=NIH2013Diag/>
| prevention      =
| treatment       = 減肥、運動<ref name=Mor2015/><ref name=Gia2009/>
| medication      = [[避孕药|避孕药]]、[[二甲双胍|二甲双胍]]、[[抗雄激素|抗雄激素]]<ref name=NIH2014Tx1/>
| prognosis       =
| frequency       = 適產年齡 2% 至 20% 的女性<ref name=NIH2013Epi/><ref name=Lub2013>{{cite book|last1=editor|first1=Lubna Pal,|title=Polycystic Ovary Syndrome Current and Emerging Concepts.|date=2013|publisher=Springer|location=Dordrecht|isbn=9781461483946|page=7|url=https://books.google.com/books?id=DTUnAQAAQBAJ&lpg=PP1&dq=Polycystic%20Ovary%20Syndrome%3B%20Subtitle%3A%20Current%20and%20Emerging%20Concepts%3B%20Part%20I&pg=PA7|chapter=Diagnostic Criteria and Epidemiology of PCOS|deadurl=no|archiveurl=https://web.archive.org/web/20170910181322/https://books.google.com/books?id=DTUnAQAAQBAJ&lpg=PP1&dq=Polycystic%20Ovary%20Syndrome%3B%20Subtitle%3A%20Current%20and%20Emerging%20Concepts%3B%20Part%20I&pg=PA7|archivedate=2017-09-10|df=}}</ref>
| deaths          = 
}}
<!-- Definition and symptoms -->
'''多囊性卵巢綜合症'''（{{lang|en|Polycystic ovary syndrome}}，簡稱'''PCOS'''），又稱'''斯-李二氏症'''（{{lang|en|Stein-Leventhal syndrome}}），是一連串女性因為[[雄性激素|雄性激素]]上升所導致的症狀<ref name=NIH2013Def>{{cite web|title=Polycystic Ovary Syndrome (PCOS): Condition Information|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/default.aspx|website=US Department of Health and Human Services, National Institutes of Health|accessdate=13 March 2015|date=2013-05-23|archive-url=https://web.archive.org/web/20150304124415/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/default.aspx|archive-date=2015-03-04|dead-url=no}}</ref>。多囊性卵巢的症狀包含[[月經|月經]]不規律或是無[[月經|月經]]、[[Menorrhagia|月經量過多]]、[[多毛症|多毛症]]、[[粉刺|粉刺]]、盆腔疼痛、[[不孕|難以受孕]]與[[黑棘皮症|黑棘皮症]]<ref name=NIH2013Sym>{{cite web|title=What are the symptoms of PCOS?|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/symptoms.aspx|website=www.nichd.nih.gov|accessdate=13 March 2015|format=05/23/2013|deadurl=no|archiveurl=https://web.archive.org/web/20150303190314/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/symptoms.aspx|archivedate=3 March 2015|df=}}</ref>。相關的病症包含[[第二型糖尿病|第二型糖尿病]]、[[肥胖症|肥胖症]]、[[阻塞性睡眠呼吸暫停|阻塞性睡眠呼吸暫停]]、[[心血管疾病|心血管疾病]]、[[情感障礙|情感障礙]]與[[子宮內膜癌|子宮內膜癌]]<ref name=NIH2013Def/>。

<!-- Cause and diagnosis -->
多囊性卵巢會受基因遺傳與環境因素影響<ref name=De2016>{{cite journal |vauthors=De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F |title=Genetic, hormonal and metabolic aspects of PCOS: an update |journal=Reproductive Biology and Endocrinology : RB&E |volume=14 |issue=1 |pages=38 |year=2016 |pmid=27423183 |pmc=4947298 |doi=10.1186/s12958-016-0173-x |type=Review}}</ref><ref name=Endo2006>{{cite journal |authors = Diamanti-Kandarakis E, Kandarakis H, Legro RS | title = The role of genes and environment in the etiology of PCOS | journal = Endocrine | volume = 30 | issue = 1 | pages = 19–26 | year = 2006 | pmid = 17185788 | doi = 10.1385/ENDO:30:1:19 }}</ref>。其危險因子包含[[肥胖症|肥胖症]]、運動量不足或是有家族病史<ref name=NIH2013Epi>{{cite web|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/risk.aspx|title=How many people are affected or at risk for PCOS?|date=2013-05-23|website=http://www.nichd.nih.gov|accessdate=13 March 2015|deadurl=no|archiveurl=https://web.archive.org/web/20150304124420/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/risk.aspx|archivedate=4 March 2015|df=}}</ref>。如果有以下三種症狀中的兩種便可診斷患者有多囊性卵巢：無排卵、雄性激素過高與卵巢囊腫<ref name="NIH2013Def" />。囊腫可以由[[超音波|超音波]]影像檢測<!-- <ref name=NIH2013Diag/> -->。其他造成類似症狀的疾病包含[[先天性腎上腺增生症|先天性腎上腺增生症]]，[[甲狀腺機能低下症|甲狀腺機能低下症]]與{{le|高泌乳素血症|hyperprolactinemia}}<ref name="NIH2013Diag">{{cite web|title=How do health care providers diagnose PCOS?|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/diagnose.aspx|website=http://www.nichd.nih.gov/|accessdate=13 March 2015|date=2013-05-23|archive-url=https://web.archive.org/web/20150402164900/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/diagnose.aspx|archive-date=2015-04-02|dead-url=no}}</ref>。

<!-- Prevention and treatment -->
多囊性卵巢綜合症目前並無特效藥可以治療<ref name=NIH2013Cure>{{cite web|title=http://www.nichd.nih.gov|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/cure.aspx|website=Is there a cure for PCOS?|accessdate=13 March 2015|date=2013-05-23|archive-url=https://web.archive.org/web/20150405021527/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/cure.aspx|archive-date=2015-04-05|dead-url=no}}</ref>。現行治療方式包括減重和運動等生活型態調整<ref name=Gia2009>{{cite journal |vauthors=Giallauria F, Palomba S, Vigorito C, Tafuri MG, Colao A, Lombardi G, Orio F |title=Androgens in polycystic ovary syndrome: the role of exercise and diet |journal=Seminars in Reproductive Medicine |volume=27 |issue=4 |pages=306–15 |year=2009 |pmid=19530064 |doi=10.1055/s-0029-1225258 |type=Review}}</ref><ref name=Mor2015>{{cite journal |vauthors=Mortada R, Williams T |title=Metabolic Syndrome: Polycystic Ovary Syndrome |journal=FP Essentials |volume=435 |issue= |pages=30–42 |year=2015 |pmid=26280343 |doi= |type=Review}}</ref><!-- <ref name=NIH2014Tx2/> -->，[[避孕藥物|避孕藥物]]對於調整經期、抑制多餘的毛髮生長與改善青春痘有所幫助<!-- <ref name=NIH2014Tx1/> -->。[[二甲双胍|二甲双胍]]和[[抗雄性激素|抗雄性激素]]可能能夠改善多囊性卵巢綜合症<!-- <ref name=NIH2014Tx1/> -->，且針對青春痘和多毛等症狀的症狀治療有一定效果<ref name=NIH2014Tx1>{{cite web|title=Treatments to Relieve Symptoms of PCOS|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/relieve.aspx|website=http://www.nichd.nih.gov/|accessdate=13 March 2015|date=2014-07-14|archive-url=https://web.archive.org/web/20150402132607/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/relieve.aspx|archive-date=2015-04-02|dead-url=no}}</ref>。減重或是使用[[可洛米分|可洛米分]]、降血糖藥物[[每福敏|每福敏]]則有助於改善不孕的狀況<!-- <ref name=NIH2014Tx2/> -->。若以上治療對於病人都沒有效果且病人有生育考量，則可考慮[[體外人工授精|體外人工授精]]這個選項<ref name=NIH2014Tx2>{{cite web|title=Treatments for Infertility Resulting from PCOS|url=http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/infertility.aspx|website=http://www.nichd.nih.gov/|accessdate=13 March 2015|date=2014-07-14|archive-url=https://web.archive.org/web/20150402200400/http://www.nichd.nih.gov/health/topics/PCOS/conditioninfo/Pages/infertility.aspx|archive-date=2015-04-02|dead-url=no}}</ref>。

<!-- Epidemiology -->
多囊性卵巢綜合症是18歲到44歲女性間最常見的{{tsl|en|endocrine disorder|內分泌疾病}}<ref name="BMC2010">{{cite journal | authors = Teede H, Deeks A, Moran L | title = Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan | journal = BMC Med | volume = 8 | pages = 41 | year = 2010 | pmid = 20591140 | pmc = 2909929 | doi = 10.1186/1741-7015-8-41 | issue=1}}</ref>。一般認為，多囊卵巢綜合症的發生率，在女性生育年齡期間佔約百分之二十（根據鹿特丹診斷指引，英國為百分之26、澳洲為百分之17.8、土耳其為百分之19.9、伊朗為百分之15.2<ref>Diagnostic Criteria and Epidemiology of PCOS; Heather R. Burks and Robert A. Wild; Book Title: Polycystic Ovary Syndrome; Subtitle: Current and Emerging Concepts; Part I; Pages: pp 03-10; Copyright: 2014; DOI: 10.1007/978-1-4614-8394-6_17; Print [[Special:网络书源/9781461483939|ISBN 978-1-4614-8393-9]]; Online [[Special:网络书源/9781461483946|ISBN 978-1-4614-8394-6]]; Publisher: Springer New York. (http://link.springer.com/chapter/10.1007/978-1-4614-8394-6_17).</ref>。）多囊卵巢綜合症是現今導致不孕的主要原因之一<ref name="NIH2013Def" />。目前已知最早的多囊卵巢綜合症病例於1721年紀錄於義大利<ref name="Kovacs2007">{{cite book|last1=Kovacs|first1=Gabor T.|last2=Norman|first2=Robert|title=Polycystic Ovary Syndrome|url=https://books.google.com/books?id=bpn1u9hziVgC&pg=PA4|accessdate=29 March 2013|date=2007-02-22|publisher=Cambridge University Press|isbn=9781139462037|page=4|archive-url=https://web.archive.org/web/20160419085106/https://books.google.com/books?id=bpn1u9hziVgC&pg=PA4|archive-date=2016-04-19|dead-url=no}}</ref>。{{TOC limit|3}}
== 體徵及症狀 ==
<!--{{Further|Infertility in polycystic ovary syndrome}}--->
常見的體徵和症狀如下：
* [[月經失調|月經失調]]： 多囊卵巢綜合症主要導致月經次數過少（一年月經次數少於九次）或[[閉經|閉經]]（沒有月經連續三到數個月以上），也可能造成其他類型的月經失調<ref name=BMC2010 /><ref name="MayoClinic" />。
* [[不孕|不孕]]<ref name="MayoClinic" />：  這是一個由慢性{{le|無排卵|Anovulation|無排卵}}導致的常見症狀 (缺乏排卵)<ref name=BMC2010 />。
* 雄性激素分泌過多： 即為{{le|雄性素過多症|hyperandrogenism|雄性素過多症}}。最常見的症狀為[[痤瘡|痤瘡]]和[[多毛症|多毛症]]，也可能導致[[月經過多|月經過多]] （週期長且量多的月經週期）， {{le|雄激素過多型脫髮症|androgenic alopecia|雄激素過多型脫髮症}} （增加毛髮脫落程度及瀰漫性脫髮）， 或其他症狀<ref name=BMC2010 /><ref name="AMN">{{cite web|author1=Christine Cortet-Rudelli|author2=Didier Dewailly|title=Diagnosis of Hyperandrogenism in Female Adolescents|work=Hyperandrogenism in Adolescent Girls|url=http://www.health.am/gyneco/more/diagnosis-of-hyperandrogenism-in-female/|date=Sep 21, 2006|publisher=Armenian Health Network, Health.am|accessdate=2006-11-21|archive-url=https://web.archive.org/web/20070930181313/http://www.health.am/gyneco/more/diagnosis-of-hyperandrogenism-in-female/|archive-date=2007-09-30|dead-url=no}}</ref>。 約有四分之三的多囊卵巢綜合症女性患者 （根據 NIH/NICHD 1990的診斷標準)）有出現{{le|高雄性素血症|hyperandrogenemia|高雄性素血症}}的症狀<ref name="huang">{{cite journal | vauthors = Huang A, Brennan K, Azziz R | title = Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria | journal = Fertil. Steril. | volume = 93 | issue = 6 | pages = 1938–41 | year = 2010 | pmid = 19249030 | doi = 10.1016/j.fertnstert.2008.12.138 | pmc=2859983}}</ref>。
* [[代謝症候群|代謝症候群]]：<ref name="MayoClinic" />有[[肚腩贅肉|肚腩贅肉]]且出現與[[胰島素抗性|胰島素抗性]]有關的症狀<ref name=BMC2010 />。 罹患多囊卵巢綜合症的女性的血清中[[胰島素|胰島素]]與升半胱胺酸濃度較正常女性來的高且有胰島素抗性<ref name="FertSter_insulin">{{cite journal | vauthors = Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M | title = The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome | journal = Fertil. Steril. | volume = 93 | issue = 6 | pages = 1864–9 | year = 2010 | pmid = 19171332 | doi = 10.1016/j.fertnstert.2008.12.024 }}</ref>。

== 原因 ==
多囊卵巢綜合症為一種成因不明的異質性失調。<ref name="MayoClinic" /><ref name=Fauser2011>Page 836 (Section:''Polycystic ovary syndrome'') in: {{cite journal | vauthors = Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, Howles CM | title = Contemporary genetic technologies and female reproduction | journal = Hum. Reprod. Update | volume = 17 | issue = 6 | pages = 829–47 | year = 2011 | pmid = 21896560 | doi = 10.1093/humupd/dmr033 | pmc=3191938}}</ref><ref name=FertSter_molecular>{{cite journal | vauthors = Legro RS, Strauss JF | title = Molecular progress in infertility: polycystic ovary syndrome | journal = Fertil. Steril. | volume = 78 | issue = 3 | pages = 569–76 | year = 2002 | pmid = 12215335 | doi = 10.1016/S0015-0282(02)03275-2 }}</ref> 有一些證據如: 家族病例、同卵雙胞胎相比異卵雙胞胎在多囊卵巢綜合症的內分泌和代謝之遺傳性特徵上有較高的一致性等，點出多囊性卵巢綜合症可能為遺傳性疾病<ref name="Endo2006" /><ref name="Fauser2011" /><ref name="FertSter_molecular" />。亦有證據表明若胎兒於子宮中暴露於高濃度的[[雄性激素|雄性激素]]與[[抗穆氏管荷爾蒙|抗穆氏管荷爾蒙]]中，隨著年紀增長會提升其患多囊卵巢綜合症的風險。<ref>{{cite journal|last1=Filippou|first1=P|last2=Homburg|first2=R|title=Is foetal hyperexposure to androgens a cause of PCOS?|journal=Human Reproduction Update|date=1 July 2017|volume=23|issue=4|pages=421–432|doi=10.1093/humupd/dmx013|pmid=28531286}}</ref>
=== 基因 ===
致病性的基因為體染色體顯性遺傳，在女性身上具有高度的基因外顯性且多變的表現度；這代表小孩有50%的機率從雙親其中一方獲得可能致病的基因片段，如果獲得此基因片段的為女兒，則會出現一定程度上的病徵<ref name="FertSter_molecular" /><ref name="pmid11212071" /><ref name="AnnNYAS_thoughts" /><ref name="OMIM" />。  異變基因可能從父母雙方遺傳而來，也可能遺傳給兒女(可能成為帶原者或是早期[[脫髮|脫髮]]或毛髮過多症狀者) <ref name="pmid11212071">{{cite journal | vauthors = Crosignani PG, Nicolosi AE | title = Polycystic ovarian disease: heritability and heterogeneity | journal = Hum. Reprod. Update | volume = 7 | issue = 1 | pages = 3–7 | year = 2001 | pmid = 11212071 | doi = 10.1093/humupd/7.1.3 }}</ref><ref name="OMIM">{{cite web|url=http://omim.org/entry/184700|work=[[人類孟德爾遺傳學|OMIM]]|title=POLYCYSTIC OVARY SYNDROME 1; PCOS1|accessdate=15 November 2011|publisher=McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine|author=Ada Hamosh|date=12 September 2011|archive-url=https://web.archive.org/web/20150716182537/http://omim.org/entry/184700|archive-date=2015-07-16|dead-url=no}}</ref>。

[[表現型|表現型]]：有一部分患者個疾病表現為{{Le|卵泡膜|theca of follicle}}分泌過多的雄性素 <ref name="AnnNYAS_thoughts">{{cite journal | vauthors = Strauss JF | title = Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome | journal = Ann. N. Y. Acad. Sci. | volume = 997 | pages = 42–8 | year = 2003 | pmid = 14644808 | doi = 10.1196/annals.1290.005 | bibcode = 2003NYASA.997...42S }}</ref>。確切的基因影響方式尚未被確認<ref name="Endo2006" /><ref name="FertSter_molecular" /><ref name="pmid15380142">{{cite journal | vauthors = Amato P, Simpson JL | title = The genetics of polycystic ovary syndrome | journal = Best Pract Res Clin Obstet Gynaecol | volume = 18 | issue = 5 | pages = 707–18 | year = 2004 | pmid = 15380142 | doi = 10.1016/j.bpobgyn.2004.05.002 }}</ref>。在少數的案例，單個基因的突變有可能造成綜合性的突變症狀<ref>{{cite journal | author = Draper | year = 2003 | title =  Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency| url = | journal = Nature Genetics | volume = 34 | issue = | pages = 434–439 | doi = 10.1038/ng1214 | pmid=12858176|display-authors=etal}}</ref>。目前對該綜合症的發病病理機致的研究指出，多囊卵巢綜合症為複雜的多基因疾病<ref>{{cite journal | author = Ehrmann David A | year = 2005 | title = Polycystic Ovary Syndrome | url = | journal = N Engl J Med | volume = 352 | issue = | pages = 1223–1236 | doi = 10.1056/NEJMra041536 }}</ref>。

多囊卵巢綜合症症狀的嚴重程度似乎主要取決於[[肥胖症|肥胖症]]<ref name="Endo2006" /><ref name=BMC2010 /><ref name="pmid28416368">{{cite journal |vauthors=Faghfoori Z, Fazelian S, Shadnoush M, Goodarzi R |title=Nutritional management in women with polycystic ovary syndrome: A review study |journal=Diabetes & Metabolic Syndrome |volume= |issue= |pages= |year=2017 |pmid=28416368 |doi=10.1016/j.dsx.2017.03.030 |type=Review}}</ref>。

多囊卵巢綜合症可視為一種[[代謝疾病|代謝疾病]]，其的部分症狀為「可逆的」。 即便多囊卵巢綜合症由28個症狀組成，但其仍被視為一種婦科疾病。

即使多囊卵巢綜合症的病名表明卵巢為該疾病的病理核心,但是囊腫為一種症況而非病因。就算兩個卵巢被摘除，部分多囊卵巢綜合症的症狀仍會持續下去，其症狀在不存在囊種的狀況下仍有可能出現。自從1935年Stein和Leventhal首次描述以來，診斷、症狀和致病因素的標準仍為爭議的主題之一。因為卵巢為首要受影響的器官，婦科學者們通常視其為一種婦科疾病。然而，近年來許多觀察顯示多囊性卵巢唯一種多重系統性失調疾病，主要問題源自於[[下視丘|下視丘]]賀爾蒙調節失調 ，許多器官也與此調節有關。多囊性卵巢這個名稱源自於[[超聲波|超聲波]]診斷之影像。多囊性卵巢綜合症的症狀非常多變，且只有約百分之15的患者可由超音波影像看出其卵巢中有囊腫。<ref>{{cite journal | vauthors = Dunaif A, Fauser BC | title = Renaming PCOS—a two-state solution | journal = J. Clin. Endocrinol. Metab. | volume = 98 | issue = 11 | pages = 4325–8 | year = 2013 | pmid = 24009134 | doi = 10.1210/jc.2013-2040 | pmc=3816269}}</ref>

=== 環境 ===
多囊卵巢綜合症可能與產前經期、[[表觀遺傳學|表觀遺傳學]]因子、環境影響（尤其是工業中產生的[[內分泌干擾素|內分泌干擾素]]<ref name=":71">{{cite journal | vauthors = Palioura E, Diamanti-Kandarakis E | title = Industrial endocrine disruptors and polycystic ovary syndrome | journal = J. Endocrinol. Invest. | volume = 36 | issue = 11 | pages = 1105–11 | year = 2013 | pmid = 24445124 | doi=10.1007/bf03346762}}</ref>如[[雙酚Ａ|雙酚Ａ]]與特定藥物）及肥胖比例增加有關，上述任何原因之一都有可能是使病症惡化的緣由。<ref name=":71" /><ref name=":72">{{cite journal | vauthors = Hoeger KM | title = Developmental origins and future fate in PCOS | journal = Semin. Reprod. Med. | volume = 32 | issue = 3 | pages = 157–158 | year = 2014 | pmid = 24715509 | doi = 10.1055/s-0034-1371086 }}</ref><ref name=":45">{{cite journal | vauthors = Harden CL | title = Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease | journal = Epilepsy Curr | volume = 5 | issue = 4 | pages = 142–6 | year = 2005 | pmid = 16151523 | pmc = 1198730 | doi = 10.1111/j.1535-7511.2005.00039.x }}</ref><ref name=":41">{{cite journal | vauthors = Rasgon N | title = The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence | journal = J Clin Psychopharmacol | volume = 24 | issue = 3 | pages = 322–34 | year = 2004 | pmid = 15118487 | doi=10.1097/01.jcp.0000125745.60149.c6}}</ref><ref name=":42">{{cite journal | vauthors = Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C | title = A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy | journal = Epilepsy Res. | volume = 97 | issue = 1–2 | pages = 73–82 | year = 2011 | pmid = 21820873 | doi = 10.1016/j.eplepsyres.2011.07.006 }}</ref><ref name=":46">{{cite journal | vauthors = Abbott DH, Barnett DK, Bruns CM, Dumesic DA | title = Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? | journal = Hum. Reprod. Update | volume = 11 | issue = 4 | pages = 357–74 | year = 2005 | pmid = 15941725 | doi = 10.1093/humupd/dmi013 }}</ref><ref name=":48">{{cite journal | vauthors = Rutkowska A, Rachoń D | title = Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS) | journal = Gynecol. Endocrinol. | volume = 30 | issue = 4 | pages = 260–5 | year = 2014 | pmid = 24397396 | doi = 10.3109/09513590.2013.871517 }}</ref>

== 發病機制 ==
多囊性卵巢的發展會刺激卵巢持續製造分泌過量的雄性激素，尤其是睪固酮，通常會伴隨著以下的其中一個症狀或是兩者皆有（幾乎肯定其具有遺傳易受性<ref name="AnnNYAS_thoughts"/>）：
*腦下垂體前葉分泌過量的[[黃體激素|黃體激素]]{{Citation needed|time=November 2011}}
*血液中[[胰岛素|胰島素]]濃度高（[[高胰島素血症|高胰島素血症]]）的女性，[[卵巢|卵巢]]對於高胰島素濃度刺激敏感<ref name=MayoClinic>{{cite web|url=http://www.mayoclinic.com/health/polycystic-ovary-syndrome/DS00423/METHOD=print&DSECTION=all|author=Mayo Clinic Staff|publisher=Mayo Clinic|work=MayoClinic.com|title=Polycystic Ovary Syndrome – All|date=4 April 2011|accessdate=15 November 2011|archive-url=https://web.archive.org/web/20130530130918/http://www.mayoclinic.com/health/polycystic-ovary-syndrome/DS00423/METHOD%3Dprint%26DSECTION%3Dall|archive-date=2013-05-30|dead-url=no}}</ref>

多囊性卵巢綜合症因其在超音波診斷中普遍可見的大量卵巢囊腫聞名。這些「囊腫」其實是未成熟的[[濾泡|濾泡]]而非囊腫。這些濾泡由初級濾泡發育而成， 但在空腔濾泡期早期因為卵巢功能停止發育，這些濾泡會出現在卵巢周邊，在超音波檢驗的影像中看起來像成串的珍珠{{Citation needed|time=November 2011}}。

患有多囊性卵巢症候群的婦女因為下視丘釋放促性腺激素釋放激素的頻率增加，導致黃體成長激素與濾泡刺激素的比值升高<ref>{{cite journal | vauthors = Lewandowski KC, Cajdler-Łuba A, Salata I, Bieńkiewicz M, Lewiński A | title = The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS) | journal = Endokrynol Pol | volume = 62 | issue = 2 | pages = 120–8 | year = 2011 | pmid = 21528473 }}</ref>。

大多數具有PCOS的婦女具有胰島素抵抗或肥胖的症狀。 他們的胰島素濃度異常的提高導致「{{le|下丘腦-垂體-性腺軸|Hypothalamic–pituitary–gonadal axis|下丘腦-垂體-卵巢軸}}」區域中的異常並引起PCOS的症狀。高胰島素血症提高[[促性腺激素释放激素|GnRH]]的釋放頻率、黃體成長激素量多過濾泡刺激素，因而佔了主導地位、增加卵巢雄激素的產生、減少濾泡的成熟並減少[[性激素结合球蛋白|SHBG]]的作用<ref name=MayoClinic />。此外，過多的胰島素<!--, acting through its cognate receptor in the presence of component cAMP signalling,-->會透過{{le|磷脂醯肌醇激酶|PI3K|PI3K}}調高{{le|17α羥化酶|17α-hydroxylase}}的活性，而17α羥化酶的活性也和雄激素前体的合成有關<ref>{{cite journal|last1=Munir|first1=Iqbal|last2=Yen|first2=Hui-Wen|last3=Geller|first3=David H.|last4=Torbati|first4=Donna|last5=Bierden|first5=Rebecca M.|last6=Weitsman|first6=Stacy R.|last7=Agarwal|first7=Sanjay K.|last8=Magoffin|first8=Denis A.|title=Insulin Augmentation of 17α-Hydroxylase Activity Is Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-Regulated Kinase-1/2 in Human Ovarian Theca Cells|journal=Endocrinology|date=January 2004|volume=145|issue=1|pages=175–183|doi=10.1210/en.2003-0329}}</ref>，因此過多胰島素的幾個效果都會提高PCOS的風險<ref>{{cite journal|last1=Diamanti-Kandarakis|first1=Evanthia|last2=Dunaif|first2=Andrea|title=Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications|journal=Endocrine Reviews|date=December 2012|volume=33|issue=6|pages=981–1030|doi=10.1210/er.2011-1034|pmid=23065822}}</ref>。胰島素抵抗是女性常見的情形，在正常體重的女性及體重過重的女性都可能會出現<ref name=Mor2015/><ref name=BMC2010 /><ref name="FertSter_insulin"/>。
{{transh}} 
Adipose tissue possesses {{tsl|en|aromatase||aromatase}}, an enzyme that converts androstenedione to estrone and testosterone to estradiol. The excess of adipose tissue in obese women creates the paradox of having both excess androgens (which are responsible for hirsutism and {{tsl|en|virilization||virilization}}) and estrogens (which inhibits FSH via negative feedback).<ref>Kumar Cotran Robbins: Basic Pathology 6th ed. / Saunders 1996{{page needed|time=February 2015}}</ref>

PCOS may be associated with chronic inflammation,<ref name=MayoClinic /><ref name=Mediators_Inflammation>{{cite journal | vauthors = Sathyapalan T, Atkin SL | title = Mediators of inflammation in polycystic ovary syndrome in relation to adiposity | journal = Mediators Inflamm. | volume = 2010 | pages = 1–5 | year = 2010 | pmid = 20396393 | doi = 10.1155/2010/758656 | pmc=2852606}}</ref>with several investigators correlating inflammatory mediators with anovulation and other PCOS symptoms.<ref>{{cite journal | vauthors = Fukuoka M, Yasuda K, Fujiwara H, Kanzaki H, Mori T | title = Interactions between interferon gamma, tumour necrosis factor alpha, and interleukin-1 in modulating progesterone and oestradiol production by human luteinized granulosa cells in culture | journal = Hum. Reprod. | volume = 7 | issue = 10 | pages = 1361–4 | year = 1992 | pmid = 1291559 }}</ref><ref>{{cite journal | vauthors = González F, Rote NS, Minium J, Kirwan JP | title = Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome | journal = J. Clin. Endocrinol. Metab. | volume = 91 | issue = 1 | pages = 336–40 | year = 2006 | pmid = 16249279 | doi = 10.1210/jc.2005-1696 }}</ref>Similarly, there seems to be a relation between PCOS and increased level of [[氧化应激|oxidative stress]].<ref name="pmid23303572">{{cite journal | vauthors = Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF | title = Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 19 | issue = 3 | pages = 268–88 | year = 2013 | pmid = 23303572 | doi = 10.1093/humupd/dms059 }}</ref>

It has previously been suggested that the excessive androgen production in PCOS could be caused by a decreased serum level of {{tsl|en|IGFBP-1||IGFBP-1}}, in turn increasing the level of free [[胰岛素样生长因子1|IGF-I]], which stimulates ovarian androgen production, but recent data concludes this mechanism to be unlikely.<ref>{{cite journal | vauthors = Kelly CJ, Stenton SR, Lashen H | title = Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 17 | issue = 1 | pages = 4–16 | year = 2010 | pmid = 20634211 | doi = 10.1093/humupd/dmq027 }}</ref>


目前研究指出多囊性卵巢綜合症與特定的基因型{{tsl|en|FMR1||FMR1}}亞型有關. The research suggests that women with ''heterozygous-normal/low'' FMR1 have polycystic-like symptoms of excessive follicle-activity and hyperactive ovarian function.<ref>{{cite journal | vauthors = Gleicher N, Weghofer A, Lee IH, Barad DH | title = FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance | journal = PLoS ONE | volume = 5 | issue = 12 | pages = e15303 | year = 2010 | pmid = 21179569 | doi = 10.1371/journal.pone.0015303 | bibcode = 2010PLoSO...515303G | pmc=3002956}}</ref>

[[跨性別男性|跨性別男性]] 如果選擇服用賀爾蒙來做為性別轉換療程的一環，他們有可能因為體內睪固酮濃度提高，導致出現多囊性卵巢症候群症狀的機率提高。 <ref name="obgyn.net">http://www.obgyn.net/articles/transgenderpcos{{full citation needed|date=February 2015}}</ref><ref>{{cite web |url=http://www.cancer-network.org/cancer_information/transgender_gender-nonconforming_people_and_cancer/transgender_men_and_ovarian_cancer.php |title=存档副本 |accessdate=2015-05-05 |deadurl=yes |archiveurl=https://web.archive.org/web/20150510002553/http://cancer-network.org/cancer_information/transgender_gender-nonconforming_people_and_cancer/transgender_men_and_ovarian_cancer.php |archivedate=2015-05-10 }}{{full citation needed|date=February 2015}}</ref>
{{trans F}}

== 診斷 ==
並不是每一個多囊卵巢綜合症的病人都有出現多囊卵巢的症狀， 也並非所有卵巢曩腫的病患都有多囊卵巢綜合症的症狀；雖然[[骨盆超聲波|骨盆超聲波]] 是主要的診斷工具， 但也並不是唯一個診斷工具<ref name=emedicine_imaging />。 雖然該綜合徵與廣泛的症狀相關，最直接的診斷方法是使用鹿特丹診斷標準。
<gallery>
File:PCOS.jpg|多囊卵巢在超聲波檢查上顯示的圖樣
File:Polycystic_ovary.jpg|多囊卵巢在陰道超聲波檢查上顯示的圖樣
File:PCO polycystic ovary.jpg|多囊卵巢在超聲波檢查上顯示的圖樣
</gallery>

=== 定義 ===
以下是兩種常見的定義：

==== 美國國立衛生研究院診斷標準 ====
: 在1990年，由[[國立衛生研究院_(美國)|國立衛生研究院 (美國)]]/ {{le|美國國家兒童健康與人類發展中心|NICHD|美國國家兒童健康與人類發展中心}}贊助的協商研討會提出，如果一個人具有以下所有症狀，表示該員罹患多囊卵巢綜合症<ref name=emedicine_main>{{cite web|url=http://emedicine.medscape.com/article/256806-overview#showall|title=Polycystic Ovarian Syndrome|author=Richard Scott Lucidi|date=25 October 2011|accessdate=19 November 2011|publisher=[[eMedicine|eMedicine]]|archive-url=https://web.archive.org/web/20111110153220/http://emedicine.medscape.com/article/256806-overview#showall|archive-date=2011-11-10|dead-url=no}}</ref>:
# 出現[[排卵不規則|排卵不規則]]的症狀
# 出現{{le|雄性素過剩|androgen excess|雄性素過剩}}的症狀 （臨床上或生化上）
# 排除可能導致月經不規則和雄激素過多的其他疾病導致上述症狀的產生

==== 鹿特丹診斷標準（Rotterdam diagnostic criteria） ====
: 2003年，[[鹿特丹|鹿特丹]] [[ESHRE|ESHRE]] / [[ASRM|ASRM]]贊助的共識研討會提出，在沒有可能導致這些發現的其他實體的情況下，如果滿足3項標準中的任何一項，多囊卵巢就會出現<ref name=BMC2010 /><ref>{{cite journal | vauthors = Azziz R | title = Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature | journal = J. Clin. Endocrinol. Metab. | volume = 91 | issue = 3 | pages = 781–5 | year = 2006 | pmid = 16418211 | doi = 10.1210/jc.2005-2153 }}</ref><ref name=HumRep_Rotterdam>{{cite journal | vauthors =  | title = Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) | journal = Hum. Reprod. | volume = 19 | issue = 1 | pages = 41–7 | year = 2004 | pmid = 14688154 | doi = 10.1093/humrep/deh098 }}</ref>：
# 出現[[排卵不規則|排卵不規則]] 或 {{le|無排卵|anovulation|無排卵}}或是兩者同時出現
# 具有{{Le|雄性素過剩|androgen excess|雄性激素過剩}}症狀
# 具有多囊卵巢症狀 (藉由 {{le|婦科超聲波|gynecologic ultrasound|婦科超聲波}}檢查）

鹿特丹診斷標準涵蓋更廣泛的有症狀婦女，最顯著的部分是在於並未有雄性素過剩的婦女也被列入在其中。 評論家認為，從研究雄激素過多的婦女獲得的結果不一定可以推廣到給沒有雄激素過剩的婦女身上<ref>{{cite journal | vauthors = Carmina E | title = Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines | journal = Minerva Ginecol | volume = 56 | issue = 1 | pages = 1–6 | year = 2004 | pmid = 14973405 }}</ref><ref>{{cite journal | vauthors = Hart R, Hickey M, Franks S | title = Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome | journal = Best Pract Res Clin Obstet Gynaecol | volume = 18 | issue = 5 | pages = 671–83 | year = 2004 | pmid = 15380140 | doi = 10.1016/j.bpobgyn.2004.05.001 }}</ref>。

;Androgen Excess PCOS Society
: 2006年，Androgen Excess PCOS Society提出了一套嚴謹診斷標準<ref name=BMC2010 />：
# 具有雄性激素過剩症狀
# 出現排卵不規則、無排卵或多囊卵巢症狀，亦或同時出現上述症狀
# 排除會引起過量雄激素活性的其他因素*

=== 標準評估 ===
*若需依據病史診斷上，月經週期、痤瘡、多毛症、肥胖症均為具體的判斷依據。 一份{{le|臨床預測規則|clinical prediction rule|臨床預測規則}}發現這四項指標在診斷PCOS方面具有77.1%的靈敏度（95%的信賴區間下62.7%–88.0%）和93.8%的特異性（95%的信賴區間下82.8%–98.7%）<ref name="pmid17872783">{{cite journal | vauthors = Pedersen SD, Brar S, Faris P, Corenblum B | title = Polycystic ovary syndrome: validated questionnaire for use in diagnosis | journal = Can Fam Physician | volume = 53 | issue = 6 | pages = 1042–7, 1041 | year = 2007 | pmid = 17872783 | pmc = 1949220 | url = http://www.cfp.ca/cgi/pmidlookup?view=long&pmid=17872783 }}</ref>。
{{transh}}{{le|婦科超聲波檢查|Gynecologic ultrasonography|婦科超聲波檢查}}, 尋找小的[[濾泡|濾泡]]為主要的檢查方式。目前確信，濾泡的功能喪失或是排軟失敗是排卵失敗或是月經不正常的狀況所造成的。 在正常的[[月經週期|月經週期]],一個卵子從濾泡中釋放，在本質上，一個囊腫破裂之後釋放出卵子。 排卵之後,殘留的濾泡變形為產生[[孕酮|孕酮]]的[[黃體|黃體]]，並會在12-14天之後消失。在多囊卵巢綜合症的案例中，有一種被稱為"濾泡捕獲(follicular arrest)"的狀況,即數個濾泡發展至5-7毫米就停止，並沒有發展至排卵前應有的大小(約16毫米或更大)。根據鹿特丹診斷標準<ref name=Mor2015/>，超聲波檢查應在卵巢中看到12個或更多的小濾泡。 <ref name=emedicine_main />更多近期的研究甚至建議，要判斷18-35歲的女性具有{{le|多囊卵巢樣形態|polycystic ovarian morphology(PCOM)|多囊卵巢樣形態}}的症狀的話，至少需要25個濾泡才能確定。<ref name="DewaillyLujan2013">{{cite journal | vauthors = Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF | title = Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society | journal = Hum. Reprod. Update | volume = 20 | issue = 3 | pages = 334–52 | year = 2013 | pmid = 24345633 | doi = 10.1093/humupd/dmt061 }}</ref>The follicles may be oriented in the periphery, giving the appearance of a 'string of pearls'.<ref name="O'Brien2011">{{cite book|last=O'Brien|first=William T.|title=Top 3 Differentials in Radiology|url=https://books.google.com/books?id=l9BmkWhvcXYC&pg=PA369|accessdate=30 August 2014|date=1 January 2011|publisher=Thieme|isbn=978-1-60406-228-1|page=369|quote=Ultrasound findings in PCOS include enlarged ovaries with peripheral follicles in a "string of pearls" configuration.|archive-url=https://web.archive.org/web/20160419092632/https://books.google.com/books?id=l9BmkWhvcXYC&pg=PA369|archive-date=2016-04-19|dead-url=no}}</ref>If a high resolution transvaginal ultrasonography machine is not available, an ovarian volume of at least 10 ml is regarded as an acceptable definition of having polycystic ovarian morphology instead of follicle count.<ref name="DewaillyLujan2013"/>
* [[laparoscopic_surgery|Laparoscopic]] examination may reveal a thickened, smooth, pearl-white outer surface of the ovary. (This would usually be an incidental finding if laparoscopy were performed for some other reason, as it would not be routine to examine the ovaries in this way to confirm a diagnosis of PCOS.){{Citation needed|time=November 2011}}
* Serum (blood) levels of [[androgen|androgen]]s (hormones associated with male development), including [[androstenedione|androstenedione]] and [[testosterone|testosterone]] may be elevated.<ref name=BMC2010 />[[Dehydroepiandrosterone_sulfate|Dehydroepiandrosterone sulfate]] levels above 700–800 µg/dL are highly suggestive of adrenal dysfunction because DHEA-S is made exclusively by the adrenal glands.<ref name="pmid18844715">{{cite journal | vauthors = Somani N, Harrison S, Bergfeld WF | title = The clinical evaluation of hirsutism | journal = Dermatol Ther | volume = 21 | issue = 5 | pages = 376–91 | year = 2008 | pmid = 18844715 | doi = 10.1111/j.1529-8019.2008.00219.x }}</ref><ref name=emedicine_workup>{{cite web|url=http://emedicine.medscape.com/article/256806-workup#showall|title=Polycystic Ovarian Syndrome Workup|publisher=[[eMedicine|eMedicine]]|date=25 October 2011|accessdate=19 November 2011|archive-url=https://web.archive.org/web/20111117180207/http://emedicine.medscape.com/article/256806-workup#showall|archive-date=2011-11-17|dead-url=no}}</ref>The free testosterone level is thought to be the best measure,<ref name=emedicine_workup /><ref name="pmid17603706">{{cite journal | vauthors = Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA | title = Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome | journal = Saudi Med J | volume = 28 | issue = 7 | pages = 1039–43 | year = 2007 | pmid = 17603706 }}</ref>with ~60% of PCOS patients demonstrating supranormal levels.<ref name="huang"/>The [[Free_androgen_index|Free androgen index]] (FAI) of the ratio of testosterone to [[sex_hormone-binding_globulin|sex hormone-binding globulin]] (SHBG) is high<ref name=BMC2010 /><ref name=emedicine_workup />and is meant to be a predictor of free testosterone, but is a poor parameter for this and is no better than testosterone alone as a marker for PCOS,<ref name="pmid1296589">{{cite journal | vauthors = Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN | title = Which hormone tests for the diagnosis of polycystic ovary syndrome? | journal = Br J Obstet Gynaecol | volume = 99 | issue = 3 | pages = 232–8 | year = 1992 | pmid = 1296589 | doi = 10.1111/j.1471-0528.1992.tb14505.x }}</ref>possibly because FAI is correlated with the degree of obesity.<ref name="pmid16409817">{{cite journal | vauthors = Li X, Lin JF | title = [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome] | language = zh | journal = Zhonghua Yi Xue Za Zhi | volume = 85 | issue = 46 | pages = 3266–71 | year = 2005 | pmid = 16409817 }}</ref>

Some other blood tests are suggestive but not diagnostic. The ratio of LH ([[Luteinizing_hormone|Luteinizing hormone]]) to FSH ([[Follicle-stimulating_hormone|Follicle-stimulating hormone]]), when measured in [[international_unit|international unit]]s, is elevated in women with PCOS. Common [[cut-off_(reference_value)|cut-off]]s to designate abnormally high LH/FSH ratios are 2:1<ref name=Banaszewska2003/>or 3:1<ref name=emedicine_workup />as tested on Day 3 of the menstrual cycle. The pattern is not very sensitive; a ratio of 2:1 or higher was present in less than 50% of women with PCOS in one study.<ref name=Banaszewska2003>{{cite journal | vauthors = Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L | title = Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia | journal = Rocz. Akad. Med. Bialymst. | volume = 48 | pages = 131–4 | year = 2003 | pmid = 14737959 }}</ref>There are often low levels of [[sex_hormone-binding_globulin|sex hormone-binding globulin]],<ref name=emedicine_workup />in particular among obese or overweight women.{{Citation needed|time=November 2011}}

[[Anti-Müllerian_hormone|Anti-Müllerian hormone]] (AMH) is increased in PCOS, and may become part of its diagnostic criteria.<ref name="pmid26691645">{{cite journal |vauthors=Dumont A, Robin G, Catteau-Jonard S, Dewailly D |title=Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review |journal=Reproductive Biology and Endocrinology : RB&E |volume=13 |issue= |pages=137 |year=2015 |pmid=26691645 |pmc=4687350 |doi=10.1186/s12958-015-0134-9 |type=Review}}</ref><ref name="pmid24430863">{{cite journal |vauthors=Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WH, Anderson RA |title=The physiology and clinical utility of anti-Mullerian hormone in women |journal=Human Reproduction Update |volume=20 |issue=3 |pages=370–85 |year=2014 |pmid=24430863 |doi=10.1093/humupd/dmt062 |type=Review}}</ref><ref name="BroerBroekmans2014">{{cite journal | vauthors = Broer SL, Broekmans FJ, Laven JS, Fauser BC | title = Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications | journal = Hum. Reprod. Update | volume = 20 | issue = 5 | pages = 688–701 | year = 2014 | pmid = 24821925 | doi = 10.1093/humupd/dmu020 }}</ref>

=== 相關條件 ===
* Fasting biochemical screen and lipid profile<ref name="emedicine_workup"/>
* 2-Hour oral [[glucose_tolerance_test|glucose tolerance test]] (GTT) in women with risk factors (obesity, family history, history of gestational diabetes)<ref name=BMC2010 />may indicate impaired glucose tolerance (insulin resistance) in 15–33% of women with PCOS.<ref name=emedicine_workup />Frank diabetes can be seen in 65–68% of women with this condition.{{Citation needed|time=November 2011|reason=Also, which criteria is this using? NIH or Rotterdam?}} Insulin resistance can be observed in both normal weight and overweight people, although it is more common in the latter (and in those matching the stricter NIH criteria for diagnosis); 50–80% of people with PCOS may have insulin resistance at some level.<ref name=BMC2010 />
* Fasting insulin level or GTT with insulin levels (also called IGTT). Elevated insulin levels have been helpful to predict response to medication and may indicate women needing higher dosages of metformin or the use of a second medication to significantly lower insulin levels. Elevated [[blood_sugar|blood sugar]] and insulin values do not predict who responds to an insulin-lowering medication, low-glycemic diet, and exercise. Many women with normal levels may benefit from combination therapy. A hypoglycemic response in which the two-hour insulin level is higher and the blood sugar lower than fasting is consistent with insulin resistance. A mathematical derivation known as the HOMAI, calculated from the fasting values in glucose and insulin concentrations, allows a direct and moderately accurate measure of insulin sensitivity (glucose-level x insulin-level/22.5).{{Citation needed|time=November 2011}}
*[[Glucose_tolerance_test|Glucose tolerance test]]ing (GTT) instead of fasting glucose can increase diagnosis of impaired glucose tolerance and frank diabetes among people with PCOS according to a prospective controlled trial.<ref name="pmid9920077">{{cite journal | vauthors = Legro RS, Kunselman AR, Dodson WC, Dunaif A | title = Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women | journal = J. Clin. Endocrinol. Metab. | volume = 84 | issue = 1 | pages = 165–9 | year = 1999 | pmid = 9920077 | doi = 10.1210/jcem.84.1.5393 | url = }}</ref>While fasting glucose levels may remain within normal limits, oral glucose tests revealed that up to 38% of asymptomatic women with PCOS (versus 8.5% in the general population) actually had impaired glucose tolerance, 7.5% of those with frank diabetes according to ADA guidelines.<ref name="pmid9920077"/>
{{trans F}}
=== 鑑別診斷 ===
應該調查其他原因，例如[[甲狀腺機能低下症|甲狀腺機能低下症]]、[[先天性腎上腺增生症|先天性腎上腺增生症]]（21-羥化酶缺乏症）、[[庫興氏症候群|庫興氏症候群]]、{{Le|高乳促素血症|hyperprolactinemia}}、雄激素分泌性腫瘤以及其他垂體或腎上腺疾病。<ref name=BMC2010 /><ref name=HumRep_Rotterdam /><ref name=emedicine_workup />

== 管理 ==
多囊卵巢綜合症的主要治疗方法包括：調整生活方式及藥物治療<ref>{{Cite journal|last=Legro|first=Richard S.|last2=Arslanian|first2=Silva A.|last3=Ehrmann|first3=David A.|last4=Hoeger|first4=Kathleen M.|last5=Murad|first5=M. Hassan|last6=Pasquali|first6=Renato|last7=Welt|first7=Corrine K.|last8=Endocrine Society|date=December 2013|title=Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline|journal=The Journal of Clinical Endocrinology and Metabolism|volume=98|issue=12|pages=4565–4592|doi=10.1210/jc.2013-2350|issn=1945-7197|pmc=5399492|pmid=24151290}}</ref>。

主要治療目標大致可分為下列四點：
* 降低病患之胰島素抗性
* 恢復生育能力
* 治療[[先天性遺傳多毛症|多毛症]]及[[痤瘡|痤瘡]]
* 恢復規律月經週期，並預防[[子宮內膜增生症|子宮內膜增生症]]和[[子宫内膜癌|子宫内膜癌]]的發生

目前現行療法中何為最佳治療方式仍是相當大的爭議，其中一個主要原因是因為缺乏比較不同療程療效的大規模臨床試驗。[[樣本_(統計學)|樣本]]往往是{{le|取樣錯誤|Sampling error|不太可靠}}因此可能產生矛盾不可靠的結果。

有助於減輕體重或降低胰島素抗性的一般干預措施對於改善多囊卵巢綜合症的症狀有益，體重增加與胰島素抗性被視為是潛在的病因。由於多囊卵巢綜合症有可能會引起嚴重的情緒障礙，因此適當的精神支持對於病情可能是有益的。<ref name="pmid22824735">{{cite journal | vauthors = Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ | title = Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies | journal = Hum. Reprod. Update | volume = 18 | issue = 6 | pages = 638–51 | year = 2012 | pmid = 22824735 | doi = 10.1093/humupd/dms029 }}</ref>

=== 飲食 ===
多囊卵巢綜合症與超重或肥胖有關，減肥是恢復規律月經的最有效方法，但是很多女性很難達到並維持顯著的體重減輕。 2013年的科學評估發現，與飲食組成無關，重量和體重組成、{{Le|懷孕率|Pregnancy rate}}、月經規律、排卵、雄激素過高、[[胰岛素抵抗|胰島素抗性]]、脂質以及生活質量均有相似的降低。<ref name=Moran2013>{{cite journal | vauthors = Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, Frearson M, Thondan M, Stepto N, Teede HJ | title = Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines | journal = Hum. Reprod. Update | volume = 19 | issue = 5 | pages = 432 | year = 2013 | pmid = 23727939 | doi = 10.1093/humupd/dmt015 }}</ref>然而，{{le|低GI飲食|low GI diet}}其中大部分的碳水化合物從水果、蔬菜和全穀物獲得，而不是[[營養素|營養素]]均衡的健康飲食，會導致更嚴重的月經失衡<ref name=Moran2013/>。

[[維生素D缺乏症|維生素D缺乏症]]可能在[[代謝症候群|代謝症候群]]的發展中發揮一定的作用，故遵照醫囑補充缺乏的營養素是極為重要的<ref name=emedicine_treatment /><ref name="pmid24044903">{{cite journal |vauthors=Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S |title=The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review |journal=European Journal of Endocrinology |volume=169 |issue=6 |pages=853–65 |year=2013 |pmid=24044903 |doi=10.1530/EJE-13-0617 |type=Review}}</ref>。然而，2015年的系統評估並沒有發現維生素D具有減輕多囊卵巢綜合症中代謝和激素失調情況的證據。<ref name="pmid26061015">{{cite journal |vauthors=He C, Lin Z, Robb SW, Ezeamama AE |title=Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis |journal=Nutrients |volume=7 |issue=6 |pages=4555–77 |year=2015 |pmid=26061015 |pmc=4488802 |doi=10.3390/nu7064555 |type=Meta-analysis}}</ref>截至2012年，使用[[營養補充品|營養補充品]]預防多囊卵巢綜合症患者代謝缺陷的干預措施已經在小型、不受控制的和非隨機的臨床試驗中進行了測試；而所得數據不足以推薦使用。<ref>{{cite journal|last1=Huang|first1=G|last2=Coviello|first2=A|title=Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome.|journal=Current Opinion in Endocrinology, Diabetes and Obesity|date=December 2012|volume=19|issue=6|pages=512–9|pmid=23108199|doi=10.1097/med.0b013e32835a000e}}</ref>

=== 藥物 ===
用於治療多囊卵巢綜合症的藥物有[[避孕藥|避孕藥]]及[[二甲雙胍|二甲雙胍]]。口服避孕藥能增加體內[[性激素结合球蛋白|性激素结合球蛋白]]生產，促進游離睾酮的結合。這減少了由高睾丸激素引起的[[多毛症|多毛症狀]]，並調節恢復正常[[月經週期|月經週期]]。二甲雙胍是在[[2型糖尿病|2型糖尿病]]中常用的一種降低胰島素排斥的藥物，並在英國，美國，澳大利亞和歐盟{{le|標示外使用|Off-label use}}用來治療多囊卵巢綜合症中的胰島素排斥。在許多情況下，二甲雙胍也能協助卵巢功能並恢復正常排卵<ref name=MayoClinic /><ref name=emedicine_treatment /><ref name=Lord>{{cite journal | vauthors = Lord JM, Flight IH, Norman RJ | title = Metformin in polycystic ovary syndrome: systematic review and meta-analysis | journal = BMJ | volume = 327 | issue = 7421 | pages = 951–3 | year = 2003 | pmid = 14576245 | pmc = 259161 | doi = 10.1136/bmj.327.7421.951 }}</ref>。[[螺內酯|螺內酯]]可用於其抗雄激素作用，而[[二氟甲基鳥氨酸|二氟甲基鳥氨酸]]則可用於減少面部毛髮。較新的胰島素抵抗藥物{{le|噻唑烷二酮|thiazolidinedione|噻唑烷二酮（格列酮）}}顯示出與二甲雙胍相當的功效，但二甲雙胍具有更輕微的副作用<ref>{{Cite journal| doi = 10.1111/j.1365-2265.2010.03917.x| issn = 1365-2265| volume = 74| issue = 3| pages = 332–339| last1 = Li| first1 = X.-J.| last2 = Yu| first2 = Y.-X.| last3 = Liu| first3 = C.-Q.| last4 = Zhang| first4 = W.| last5 = Zhang| first5 = H.-J.| last6 = Yan| first6 = B.| last7 = Wang| first7 = L.-Y.| last8 = Yang| first8 = S.-Y.| last9 = Zhang| first9 = S.-H.| title = Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis| journal = Clinical Endocrinology| date = 2011-03| pmid = 21050251}}</ref><ref>{{Cite journal| issn = 1759-5029| volume = 7| issue = 3| pages = 128–| last1 = Grover| first1 = Anjali| last2 = Yialamas| first2 = Maria A.| title = Metformin or thiazolidinedione therapy in PCOS?| journal = Nature Reviews Endocrinology| accessdate = 2015-05-24| date = 2011-03| url = http://go.galegroup.com/ps/i.do?id=GALE%7CA250471047&v=2.1&u=bengurion&it=r&p=AONE&sw=w&asid=0437c3db1d07b3f81e03e5bbc5cb63d2| doi = 10.1038/nrendo.2011.16| author = | archive-url = https://web.archive.org/web/20150722083952/http://go.galegroup.com/ps/i.do?id=GALE%7CA250471047&v=2.1&u=bengurion&it=r&p=AONE&sw=w&asid=0437c3db1d07b3f81e03e5bbc5cb63d2| archive-date = 2015-07-22| dead-url = no}}</ref>。 {{le|英國國家健康與照顧卓越研究院|National Institute for Health and Clinical Excellence}}在2004年提出建議，當其他治療未能產生效果時，將給予給予[[身高體重指數|BMI]]高於25的病患服用二甲雙胍<ref name="NICE2004">{{NICE| 11 | Fertility: assessment and treatment for people with fertility problems | 2004}}</ref><ref>{{cite web |author=Balen A |title=Metformin therapy for the management of infertility in women with polycystic ovary syndrome |work=Scientific Advisory Committee Opinion Paper 13 |publisher=Royal College of Obstetricians and Gynaecologists |date=December 2008 |url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |format=PDF |accessdate=2009-12-13 |deadurl=yes |archiveurl=https://www.webcitation.org/5m73m3kuM?url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |archivedate=2009-12-18 }}</ref>。二甲雙胍在每種類型的多囊卵巢綜合症中可能並非有效的，因此對於是否應該用作一般一線治療存在一些分歧<ref name="pmid19697191">{{cite journal | vauthors = Leeman L, Acharya U | title = The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence | journal = J Obstet Gynaecol | volume = 29 | issue = 6 | pages = 467–72 | year = 2009 | pmid = 19697191 | doi = 10.1080/01443610902829414 }}</ref>。[[羟甲基戊二酸单酰辅酶A还原酶抑制剂|羟甲基戊二酸单酰辅酶A还原酶抑制剂]]在治療潛在代謝綜合徵方面的應用尚不清楚<ref>{{cite journal|last1=Legro|first1=RS|last2=Arslanian|first2=SA|last3=Ehrmann|first3=DA|last4=Hoeger|first4=KM|last5=Murad|first5=MH|last6=Pasquali|first6=R|last7=Welt|first7=CK|last8=Endocrine|first8=Society|title=Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.|journal=The Journal of Clinical Endocrinology and Metabolism|date=December 2013|volume=98|issue=12|pages=4565–92|pmid=24151290|doi=10.1210/jc.2013-2350}}</ref>。

多囊卵巢綜合症可能導致難以受孕，因為它會導致不規律[[排卵|排卵]]。試圖懷孕時，會使用誘導生育的藥物包括排卵誘導劑克羅米酚或  脈衝亮丙瑞林  。 二甲雙胍與克羅米酚組合使用時，可提高生殖治療的療效。<ref>{{Cite journal| doi = 10.1056/NEJM199806253382603| issn = 0028-4793| volume = 338| issue = 26| pages = 1876–1880| last1 = Nestler| first1 = John E.| last2 = Jakubowicz| first2 = Daniela J.| last3 = Evans| first3 = William S.| last4 = Pasquali| first4 = Renato| title = Effects of Metformin on Spontaneous and Clomiphene-Induced Ovulation in the Polycystic Ovary Syndrome| journal = New England Journal of Medicine| accessdate = 2015-05-24| date = 1998-06-25| url = http://dx.doi.org/10.1056/NEJM199806253382603| pmid = 9637806}}</ref>二甲雙胍被認為在懷孕期間使用是安全的，於美國的[[懷孕分級|懷孕分級]]為B<ref>{{Cite journal| doi = 10.2337/dc11-1153| issn = 0149-5992| volume = 34| issue = 10| pages = 2329–2330| last1 = Feig| first1 = Denice S.| last2 = Moses| first2 = Robert G.| title = Metformin Therapy During Pregnancy Good for the goose and good for the gosling too?| journal = Diabetes Care| accessdate = 2015-05-24| date = 2011-10-01| url = http://care.diabetesjournals.org/content/34/10/2329| pmid = 21949224| pmc = 3177745| author = | archive-url = https://web.archive.org/web/20150525185909/http://care.diabetesjournals.org/content/34/10/2329| archive-date = 2015-05-25| dead-url = no}}</ref>。2014年的評論得出結論，在三個月內使用二甲雙胍治療的女性並不會增加產下[[先天性障礙|先天性障礙]]嬰兒的風險<ref name="CassinaDona2014">{{cite journal | vauthors = Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M | title = First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 20 | issue = 5 | pages = 656–69 | year = 2014 | pmid = 24861556 | doi = 10.1093/humupd/dmu022 }}</ref>。

=== 不孕症 ===
=== 多毛症及痤瘡 ===

=== 月經不規律 ===

如果病患目前沒有懷孕需求，可以藉由服用[[複合口服避孕藥|複合口服避孕藥]]來調節[[月經|月經]]紊亂<ref name=MayoClinic /><ref name=emedicine_treatment>{{cite web|url=http://emedicine.medscape.com/article/256806-treatment#showall|title=Polycystic Ovarian Syndrome Treatment & Management|publisher=[[eMedicine|eMedicine]]|date=25 October 2011|accessdate=19 November 2011|archive-url=https://web.archive.org/web/20111116192235/http://emedicine.medscape.com/article/256806-treatment#showall|archive-date=2011-11-16|dead-url=no}}</ref>。 調理生理週期的主要目的是讓女性生活上比較方便，改善女性對於生理週期與自己的感受；若能自然規律行經，便不需藉由服藥使生理週期變得規律。


如果不期望定期的月經週期，則不一定需要不規則循環的治療。大多數專家說，如果至少每三個月發生一次月經，那麼子宮內膜就會經常流下來，以防止增加子宮內膜異常或癌症的風險。<ref name=verity_risks>{{cite web|url=http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos/health_risks|title=What are the health risks of PCOS?|work=Verity – PCOS Charity|publisher=Verity|year=2011|accessdate=21 November 2011|deadurl=yes|archiveurl=https://archive.is/20121225050404/http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos/health_risks|archivedate=2012年12月25日}}</ref> 如果月經頻率極低或根本沒來，推薦使用某些形式的助孕素。<ref name=emedicine_medications>{{cite web|url=http://emedicine.medscape.com/article/256806-medication#showall|title=Polycystic Ovarian Syndrome Medication|publisher=eMedicine|author=Richard Scott Lucidi|date=25 October 2011|accessdate=19 November 2011|deadurl=no|archiveurl=https://web.archive.org/web/20111114103933/http://emedicine.medscape.com/article/256806-medication#showall|archivedate=14 November 2011|df=}}</ref> 其中一種替代方案即是定期服用一次口服助孕素（例如，每三個月）以誘發可預測的月經出血。<ref name=MayoClinic />

=== 替代藥物 ===

一篇2017年發表的科學論文指出肌醇與D-手性肌醇可能具有調節生理週期與改善排卵的功效，然而目前仍然缺乏其是否能影響懷孕機率的證據，一篇於2011年發表的[[綜述文章|綜述文章]]亦指出目前缺乏足夠的證據去證明D-手性肌醇具有任何功效。 <ref>{{cite journal|last1=Pundir|first1=J|last2=Psaroudakis|first2=D|last3=Savnur|first3=P|last4=Bhide|first4=P|last5=Sabatini|first5=L|last6=Teede|first6=H|last7=Coomarasamy|first7=A|last8=Thangaratinam|first8=S|title=Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials|journal=BJOG : An International Journal of Obstetrics and Gynaecology|date=24 May 2017|pmid=28544572|doi=10.1111/1471-0528.14754|volume=125|issue=3|pages=299–308}}</ref><ref>{{Cite journal|last=Amoah-Arko|first=Afua|last2=Evans|first2=Meirion|last3=Rees|first3=Aled|date=2017-10-20|title=Effects of myoinositol and D-chiro inositol on hyperandrogenism and ovulation in women with polycystic ovary syndrome: a systematic review|url=http://www.endocrine-abstracts.org/ea/0050/ea0050p363.htm|doi=10.1530/endoabs.50.P363|journal=Endocrine Abstracts|author=|access-date=2019-02-22|archive-url=https://web.archive.org/web/20180812022800/https://www.endocrine-abstracts.org/ea/0050/ea0050p363.htm|archive-date=2018-08-12|dead-url=no}}</ref> <ref name="pmid21142777">{{cite journal | vauthors = Galazis N, Galazi M, Atiomo W | title = D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review | journal = Gynecol. Endocrinol. | volume = 27 | issue = 4 | pages = 256–62 | year = 2011 | pmid = 21142777 | doi = 10.3109/09513590.2010.538099 }}</ref> 兩篇分別發表於2012年與2017年的[[綜述文章|綜述文章]]點出補充[[肌醇|肌醇]]似乎能夠有效改善多囊性卵巢綜合症的幾種激素紊亂，且能降低採取體外受精之女性的促性腺激素釋放激素濃度與改善其卵巢過度刺激症的發作時間。<ref name="pmid22296306">{{cite journal | vauthors = Unfer V, Carlomagno G, Dante G, Facchinetti F | title = Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials | journal = Gynecol. Endocrinol. | volume = 28 | issue = 7 | pages = 509–15 | year = 2012 | pmid = 22296306 | doi = 10.3109/09513590.2011.650660 }}</ref><ref>{{Cite journal|last=Zeng|first=Liuting|last2=Yang|first2=Kailin|date=2017-10-19|title=Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis|journal=Endocrine|pages=30–38|doi=10.1007/s12020-017-1442-y|pmid=29052180|issn=1355-008X|volume=59|issue=1}}</ref> <ref>{{Cite journal|last=Laganà|first=Antonio Simone|last2=Vitagliano|first2=Amerigo|last3=Noventa|first3=Marco|last4=Ambrosini|first4=Guido|last5=D'Anna|first5=Rosario|date=2018-08-04|title=Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials|journal=Archives of Gynecology and Obstetrics|volume=298|issue=4|pages=675–684|doi=10.1007/s00404-018-4861-y|issn=1432-0711|pmid=30078122}}</ref> 對於針灸是否能改善多囊性卵巢綜合症方面，目前仍然缺乏足夠的科學證據來證實其效用。<ref>{{Cite journal|last=Lim|first=Chi Eung Danforn|last2=Ng|first2=Rachel W. C.|last3=Xu|first3=Ke|last4=Cheng|first4=Nga Chong Lisa|last5=Xue|first5=Charlie C. L.|last6=Liu|first6=Jian Ping|last7=Chen|first7=Nini|date=2016-05-03|title=Acupuncture for polycystic ovarian syndrome|journal=The Cochrane Database of Systematic Reviews|issue=5|pages=CD007689|doi=10.1002/14651858.CD007689.pub3|issn=1469-493X|pmid=27136291}}</ref><ref>{{cite journal|last1=Wu|first1=XK|last2=Stener-Victorin|first2=E|last3=Kuang|first3=HY|last4=Ma|first4=HL|last5=Gao|first5=JS|last6=Xie|first6=LZ|last7=Hou|first7=LH|last8=Hu|first8=ZX|last9=Shao|first9=XG|last10=Ge|first10=J|last11=Zhang|first11=JF|last12=Xue|first12=HY|last13=Xu|first13=XF|last14=Liang|first14=RN|last15=Ma|first15=HX|last16=Yang|first16=HW|last17=Li|first17=WL|last18=Huang|first18=DM|last19=Sun|first19=Y|last20=Hao|first20=CF|last21=Du|first21=SM|last22=Yang|first22=ZW|last23=Wang|first23=X|last24=Yan|first24=Y|last25=Chen|first25=XH|last26=Fu|first26=P|last27=Ding|first27=CF|last28=Gao|first28=YQ|last29=Zhou|first29=ZM|last30=Wang|first30=CC|last31=Wu|first31=TX|last32=Liu|first32=JP|last33=Ng|first33=EHY|last34=Legro|first34=RS|last35=Zhang|first35=H|last36=PCOSAct Study|first36=Group.|title=Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial|journal=JAMA|date=27 June 2017|volume=317|issue=24|pages=2502–2514|doi=10.1001/jama.2017.7217|pmid=28655015|pmc=5815063}}</ref>

== 預測 ==
多囊性卵巢綜合症的高風險伴隨症狀：
* 可能發生[[子宮內膜增生症|子宮內膜增生症]]和[[子宫内膜癌|子宫内膜癌]]，因為子宮內膜過度積累，且也缺乏[[孕酮|黃體素]]導致雌激素對子宮細胞的刺激延遲<ref name=MayoClinic /><ref name=emedicine_main /><ref name="BarryAzizia2014"/>。這種風險是否直接歸因於綜合徵或相關的肥胖（[[高胰島素血症|高胰島素血症]]和{{le|雄激素過多症|hyperandrogenism}}）還不清楚。<ref>{{cite journal | vauthors = New MI | title = Nonclassical congenital adrenal hyperplasia and the polycystic ovarian syndrome | journal = Ann. N. Y. Acad. Sci. | volume = 687 | pages = 193–205 | year = 1993 | pmid = 8323173 | doi = 10.1111/j.1749-6632.1993.tb43866.x | bibcode = 1993NYASA.687..193N }}</ref><ref name="pmid12781553">{{cite journal | vauthors = Hardiman P, Pillay OC, Atiomo W | title = Polycystic ovary syndrome and endometrial carcinoma | journal = Lancet | volume = 361 | issue = 9371 | pages = 1810–2 | year = 2003 | pmid = 12781553 | doi = 10.1016/S0140-6736(03)13409-5 }}</ref><ref>{{cite journal | vauthors = Mather KJ, Kwan F, Corenblum B | title = Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity | journal = Fertil. Steril. | volume = 73 | issue = 1 | pages = 150–6 | year = 2000 | pmid = 10632431 | doi = 10.1016/S0015-0282(99)00468-9 }}</ref>
* [[胰島素抗性|胰島素抗性]]或[[2型糖尿病|第二型糖尿病]]<ref name=MayoClinic />：2010年發表的一項論文得出，即使在控制[[身高體重指數|身高體重指數]]（BMI）時，多囊性卵巢綜合症患者的胰島素抗性和II型糖尿病患病率也會升高。<ref name=emedicine_main /><ref>{{cite journal | vauthors = Moran LJ, Misso ML, Wild RA, Norman RJ | title = Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 16 | issue = 4 | pages = 347–63 | year = 2010 | pmid = 20159883 | doi = 10.1093/humupd/dmq001 }}</ref>多囊性卵巢綜合症也使一個女人，容易患有[[妊娠糖尿病|妊娠糖尿病]]，特別是肥胖症患者<ref name=MayoClinic />。
* [[高血壓|高血壓]]，特別是肥胖或懷孕期間<ref name=MayoClinic />。
* [[憂鬱|憂鬱]]和[[焦慮|焦慮]]<ref name=BMC2010 /><ref>{{cite journal | vauthors = Barry JA, Kuczmierczyk AR, Hardiman PJ | title = Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis | journal = Hum. Reprod. | volume = 26 | issue = 9 | pages = 2442–51 | year = 2011 | pmid = 21725075 | doi = 10.1093/humrep/der197 }}</ref>
* {{Internal link helper/en|血脂異常|Dyslipidemia}}<ref name=MayoClinic /> （脂質代謝障礙 ） 膽固醇和三酸甘油酯。具有多囊卵巢綜合症的婦女顯示[[动脉粥样硬化|动脉粥样硬化]]去除機制會減弱，導致殘餘物，似乎與胰島素抗性或II型糖尿病無關。<ref>{{cite journal | vauthors = Rocha MP, Maranhão RC, Seydell TM, Barcellos CR, Baracat EC, Hayashida SA, Bydlowski SP, Marcondes JA | title = Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome | journal = Fertil. Steril. | volume = 93 | issue = 6 | pages = 1948–56 | year = 2010 | pmid = 19765700 | doi = 10.1016/j.fertnstert.2008.12.044 }}</ref>
* [[心血管疾病|心血管疾病]]<ref name=MayoClinic /><ref name=emedicine_main />研究分析估計有多囊性卵巢綜合症患者的動脈疾病風險相對於沒有女性的2倍，與BMI無關<ref>{{cite journal | vauthors = de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM | title = PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 17 | issue = 4 | pages = 495–500 | year = 2011 | pmid = 21335359 | doi = 10.1093/humupd/dmr001 }}</ref>。
* [[中風|中風]]<ref name=emedicine_main /><ref name=emedicine_main />
* {{le|體重增加|Weight gain}}<ref name=MayoClinic />
* [[流產|流產]]<ref name="pmid18277353">{{cite journal | vauthors = Goldenberg N, Glueck C | title = Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation | journal = Minerva Ginecol | volume = 60 | issue = 1 | pages = 63–75 | year = 2008 | pmid = 18277353 }}</ref><ref name="pmid18181085">{{cite journal | vauthors = Boomsma CM, Fauser BC, Macklon NS | title = Pregnancy complications in women with polycystic ovary syndrome | journal = Semin. Reprod. Med. | volume = 26 | issue = 1 | pages = 072–084 | year = 2008 | pmid = 18181085 | doi = 10.1055/s-2007-992927 }}</ref>
* [[睡眠呼吸暂停|睡眠呼吸中止症]]，特別是肥胖症患者<ref name=MayoClinic />
* [[非酒精性脂肪肝|非酒精性脂肪肝]]，特別是肥胖症患者<ref name=MayoClinic />
* [[黑棘皮症|黑棘皮症]]（腋下，鼠蹊部與後頸出現暗色皮膚斑紋）<ref name=emedicine_main />
* {{Internal link helper/en|自體免疫甲狀腺炎|Autoimmune thyroiditis}}<ref name="pmid21866332">{{cite journal |vauthors=Kachuei M, Jafari F, Kachuei A, Keshteli AH |title=Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome |journal=Archives of Gynecology and Obstetrics |volume=285 |issue=3 |pages=853–6 |year=2012 |pmid=21866332 |doi=10.1007/s00404-011-2040-5 |url=}}</ref>

早期診斷和治療可能會降低其中一些風險，如II型糖尿病和心臟病。<!--<ref name="MayoClinic2" />--->

卵巢癌和乳腺癌的風險總體上沒有顯著增加。<ref name="BarryAzizia2014">{{cite journal | vauthors = Barry JA, Azizia MM, Hardiman PJ | title = Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis | journal = Hum. Reprod. Update | volume = 20 | issue = 5 | pages = 748–758 | year = 2014 | pmid = 24688118 | doi = 10.1093/humupd/dmu012 | pmc=4326303}}</ref>

== 流行病學 ==
多囊性卵巢綜合症的盛行率受到診斷標準的影響。 世界衛生組織在2010年時估計全世界約有一億一千六百萬名女性（約3.4%的女性）受多囊性卵巢綜合症影響。<ref name="LancetEpi2012">{{cite journal | vauthors = Vos T, Flaxman AD, et al | title = Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | journal = Lancet | volume = 380 | issue = 9859 | pages = 2163–96 | year = 2012 | pmid = 23245607 | doi = 10.1016/S0140-6736(12)61729-2 }}</ref>一份以鹿特丹診斷診斷指引為準的多囊性卵巢綜合症流行率社區研究發現，大約有百分之18的女性患有多囊性卵巢，而這些患者約有百分之70先前並未被確診出患有多囊性卵巢綜合症。<ref name=BMC2010/>

約有百分之8到25的一般女性在超音波診斷中會看到有多囊性卵巢。<ref>{{cite journal | vauthors = Polson DW, Adams J, Wadsworth J, Franks S | title = Polycystic ovaries—a common finding in normal women | journal = Lancet | volume = 1 | issue = 8590 | pages = 870–2 | year = 1988 | pmid = 2895373 | doi=10.1016/s0140-6736(88)91612-1}}</ref><ref name=clayton>{{cite journal | vauthors = Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S, Meade TW | title = How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? | journal = Clin. Endocrinol. (Oxf) | volume = 37 | issue = 2 | pages = 127–34 | year = 1992 | pmid = 1395063 | doi = 10.1111/j.1365-2265.1992.tb02296.x }}</ref><ref name="pmid8053879">{{cite journal | vauthors = Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT | title = The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women | journal = Aust N Z J Obstet Gynaecol | volume = 34 | issue = 1 | pages = 67–72 | year = 1994 | pmid = 8053879 | doi = 10.1111/j.1479-828X.1994.tb01041.x }}</ref><ref name="pmid9091329">{{cite journal | vauthors = van Santbrink EJ, Hop WC, Fauser BC | title = Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome | journal = Fertil. Steril. | volume = 67 | issue = 3 | pages = 452–8 | year = 1997 | pmid = 9091329 | doi = 10.1016/S0015-0282(97)80068-4 }}</ref>服用口服避孕藥的女性中，有14%發現有多囊性卵巢<ref name=clayton/>。卵巢囊腫也是使用釋放[[黃體素|黃體素]]的[[子宮環|子宮環]]後常見的副作用。<ref>{{cite journal | vauthors = Hardeman J, Weiss BD | title = Intrauterine devices: an update. | journal = Am Fam Physician | volume = 89 | issue = 6 | pages = 445–50 | year = 2014 | pmid = 24695563 }}</ref>

== 歷史 ==
這種症狀最早在1935年由美國婦科醫生Irving F. Stein, Sr.與Michael L. Leventhal首次描述，其原始名稱為斯-李二氏症<ref name=emedicine_imaging>{{Cite web|url=http://emedicine.medscape.com/article/404754-overview|publisher=[[eMedicine|eMedicine]]|title=Imaging in Polycystic Ovary Disease|work=eMedicine|first=Greg|last=Marrinan|editor-first=Eugene C|editor-last=Lin|date=20 April 2011|accessdate=19 November 2011|archive-url=https://web.archive.org/web/20111108080042/http://emedicine.medscape.com/article/404754-overview|archive-date=2011-11-08|dead-url=no}}</ref><ref name=emedicine_main />
。

目前已知最早的多囊卵巢綜合症記錄，是1721年間源自義大利的記錄<ref name="Kovacs2007"/>。關於卵巢囊腫的相關變化描述最早出現在1844年<ref name="Kovacs2007" />。
==社會及文化==
=== 經費 ===
2005年在美國有約四百萬起多囊卵巢綜合症的病例，其醫療費用有43.6億美元<ref>{{cite journal |last1=Azziz |first1=Ricardo |last2=Marin |first2=Catherine |last3=Hoq |first3=Lalima |last4=Badamgarav |first4=Enkhe |last5=Song |first5=Paul |title=Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span |journal=The Journal of Clinical Endocrinology and Metabolism |date=1 August 2005 |volume=90 |issue=8 |pages=4650–4658 |doi=10.1210/jc.2005-0628 |pmid=15944216 |url=https://academic.oup.com/jcem/article/90/8/4650/2838470 |accessdate=3 December 2018 |author= |archive-url=https://web.archive.org/web/20181204040128/https://academic.oup.com/jcem/article/90/8/4650/2838470 |archive-date=2018-12-04 |dead-url=no }}</ref>。2016年國立衛生研究院的研究預算有323億美元，其中有0.1%用在多囊卵巢綜合症的研究上<ref>{{cite web |title=RCDC Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) |url=https://report.nih.gov/categorical_spending.aspx#tab1 |website=NIH |publisher=NIH |accessdate=3 December 2018 |archive-url=https://web.archive.org/web/20190228225730/https://report.nih.gov/categorical_spending.aspx#tab1 |archive-date=2019-02-28 |dead-url=no }}</ref>。

=== 名稱 ===
這種綜合徵的其他名稱包括多囊卵巢疾病、功能性卵巢雄激素過多症、{{le|卵巢濾泡膜細胞增殖|Hyperthecosis}}、硬皮囊性卵巢綜合徵和斯-李二氏症。斯-李二氏症為其原始名稱，現在使用這個名稱都僅限於具有[[不孕症|不孕症]]、[[先天性遗传多毛症|多毛症]]、卵巢有多發囊狀腫大<!--enlarged polycystic ovaries-->的[[閉經|閉經]]女性<ref name=emedicine_imaging />。

這種疾病的名稱「多囊卵巢綜合症」是因為在醫學影像中可見多囊性卵巢而得此稱<ref name=MayoClinic />。多囊性卵巢在靠近卵巢表面處有極大量正在發育的卵子，其在超音波中可用肉眼鑑別<ref name=emedicine_imaging />，看起來像許多小[[囊腫|囊腫]]<ref name=verity_what_is_PCOS>{{cite web|title=What is Polycystic Ovary Syndrome (PCOS)?|url=http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos|year=2011|accessdate=21 November 2011|work=Verity – PCOS Charity|publisher=Verity|deadurl=yes|archiveurl=https://archive.is/20121224161556/http://www.verity-pcos.org.uk/guide_to_pcos/what_is_pcos|archivedate=2012年12月24日}}</ref>。

== 參見 ==
* {{tsl|en|Androgen-dependent syndromes|雄性素依賴症候群}}
* 《{{tsl|en|PCOS Challenge|多囊卵巢綜合症挑戰}}》（真實改編電視劇）

== 參考文獻 ==
{{Reflist|32em}}{{commons category|Polycystic ovary syndrome}}
{{Endocrine pathology}}

{{DEFAULTSORT:Polycystic Ovary Syndrome}}
[[Category:婦科疾病|Category:婦科疾病]]
[[Category:與肥胖有關的醫學症狀|Category:與肥胖有關的醫學症狀]]
[[Category:症候群|Category:症候群]]
[[Category:人類繁殖|Category:人類繁殖]]
[[Category:内分泌相关皮肤疾病|Category:内分泌相关皮肤疾病]]